Diagnostic and prognostic performance of the neutrophilto-lymphocyte ratio in acute coronary syndromes: A metaanalysis of 90 studies including 45 990 patients

Michał Pruc^{1, 2}, Jacek Kubica³, Maciej Banach^{4, 5, 6, 7}, Damian Swieczkowski^{1, 8}, Zubaid Rafique⁹, William Frank Peacock⁹, Zbigniew Siudak^{1, 10}, Krzysztof Kurek¹, Prabath Nanayakkara¹¹, Łukasz Szarpak^{1, 9, 12}

¹Department of Clinical Research and Development, LUXMED Group, Warszawa, Poland

²Department of Public Health, International European University, Kyiv, Ukraine

³Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁴Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Łódź, Poland

⁵Cardiovascular Research Centre, University of Zielona Gora, Zielona Góra, Poland

⁶Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Łódź, Poland

⁷Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States

⁸Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Gdańsk, Poland

⁹Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States

¹⁰Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland

¹¹Division of Acute Medicine, Department of Internal Medicine, Amsterdam UMC, VU University, Amsterdam, the Netherlands

¹²Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Warszawa, Poland

Correspondence to:

Prof. Lukasz Szarpak, PhD, DPH, MBA, DBA, FERC, Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, One Baylor Plaza — BCM285, Houston, TX 77030, phone: +48 500 186 225, e-mail: lukasz.szarpak@gmail.com, lukasz.szarpak@bcm.edu Copyright by the Author(s), 2024 DOI: 10.33963/v.phj.99554

Received: January 21, 2024 Accepted: February 26, 2024 Early publication date: March 7, 2024

ABSTRACT

Background: Cardiovascular disease is a leading cause of mortality worldwide and is likely to rise. Acute coronary syndrome (ACS) is consequent on inflammation. As a common and cost-effective inflammatory biomarker, the neutrophil-to-lymphocyte ratio (NLR) may be beneficial in cardiovascular medicine.

Aims: This meta-analysis examines the diagnostic and prognostic performance of the NLR in ACS.

Methods: We systematically searched PubMed Central, Medline, Scopus, EMBASE, Cochrane Central Register of Controlled Trials, and Clinicaltrial.gov databases. The search spanned **inception [Inception of what??]** to January 10, 2024. The findings were aggregated into normalized mean differences with 95% confidence intervals.

Results: Ninety articles, with 45 990 participants, were included. Pooled analysis of the NLR varied and was higher in ST-segment elevation myocardial infarction (STEMI) vs. non-ST-segment elevation myocardial infarction patients (4.94 ± 3.24 vs. 3.24 ± 2.74), acute myocardial infarction vs. unstable angina (4.47 ± 3.43 vs. 2.97 ± 1.58), ACS vs. stable angina (SA) (5.45 ± 4.28 vs. 2.46 ± 2.15), and ACS vs. controls (5.31 ± 4.01 vs. 2.46 ± 2.45). The NLR also was associated with ACS mortality, with survivors having lower results (3.67 ± 2.72 vs. 5.56 ± 3.93). Subanalysis showed that differences in the NLR were observed in STEMI survivors (4.28 ± 3.24 vs. 6.79 ± 3.98). Of ACS patients with major cardiovascular events (MACE) vs. without MACE, the NLR was 6.29 ± 4.89 vs. 3.82 ± 4.12 . In STEMI patients, the NLR differed between those with and without MACE (6.99 ± 5.27 vs. 4.99 ± 4.12).

Conclusions: The NLR is an effective tool for differentiating between different types of ACS. A high NLR is associated with ACS and increased MACE at 30 days. The NLR also appears to be a good predictor of MACE risk, at least in STEMI patients.

Key words: acute coronary syndrome, biomarkers, diagnostic techniques, neutrophil-tolymphocyte ratio, prognosis

WHAT'S NEW?

Research published so far indicates that the neutrophil-to-lymphocyte ratio (NLR) may be an effective and cost-effective predictor of outcomes in conditions where inflammation has a crucial role. This meta-analysis aimed to determine the diagnostic and prognostic performance of the NLR in acute coronary syndromes (ACS). Our study showed that the NLR is an effective tool for differentiating between different types of ACS. The NLR is higher in acute myocardial infarction (AMI) vs. unstable angina (UA), ACS vs. stable angina (SA), ACS vs. controls, and between ACS survivors vs. ACS deceased. A high NLR is associated with ACS and increased major cardiovascular events (MACE) at 30 days. The NLR also appears to be a good predictor of MACE risk. Considering the above results, as well as the wide availability and cost-effectiveness of the NLR index, our meta-analysis has suggested the potential positive predictive and diagnostic properties of the NLR in ACS patients.

INTRODUCTION

The neutrophil-to-lymphocyte ratio (NLR) is a cost-effective potential inflammatory marker used to assess the prognosis in many diseases, such as COVID-19 [1], diabetes [2], head and neck cancer [3], multiple organ dysfunction syndrome [4], etc. The NLR is also recommended as a potentially useful indicator for assessing the response to neoadjuvant chemotherapy in triple-negative breast cancer [5]. The biomarker may also have applications in cardiovascular disease diagnosis and prediction. In a recently published retrospective observational study, Ha et al. showed that an NLR >3.4 is associated with worse one-year survival after percutaneous coronary intervention (91.4% vs. 95.4%, logrank P <0.004) [6]. It is also recommended to use the NLR, rather than other hematological parameters, such as white blood cell count, for 30-day mortality risk stratification in elderly patients after acute coronary syndrome (ACS) [7]. Finally, in patients with heart failure, an increased NLR was associated with increased all-cause mortality during a median follow-up of 66 months [8].

Many mechanisms related to the functioning of the immune system have been well described in the development of atherosclerosis and atherothrombosis [9, 10]. Macrophages and T lymphocytes are involved in the process of formation and development of atherosclerotic plague. Additionally, pro-inflammatory cytokines, e.g., interleukins (especially IL-1, IL-6, IL-12, and IL-18), accelerate the development of atherosclerotic lesions. Other pro-inflammatory proteins, including tumor necrosis factor-α (TNF-alpha) or macrophage colony-stimulating factor (M-CSF), have similar properties [11]. In patients with diagnosed heart failure (both with preserved and reduced ejection fraction), increased concentrations of inflammatory cytokines are observed. Elevated cytokine levels also correlate with increased risk of decompensation and negative outcomes [12, 13].

Anti-cytokine drugs may be a promising strategy in the development of cardiovascular pharmacotherapy, especially when included as part of a personalized approach [14, 15]. The introduction of these types of drugs is an additional argument in support of the pro-inflammatory etiology of cardiovascular diseases and to reduce inflammation-related residual CVD risk. Unfortunately, conducting a clinical trial with unambiguous results in this population has been

a challenge. Clinical trials to date, in most cases, have been terminated prematurely due to lack of direct benefit to participants or lack of impact on endpoints such as major adverse cardiovascular events (MACE) [16].

Overall, given the potential usefulness of the NLR in assessing prognosis in patients after ACS, this meta-analysis aims to determine NLR utility as a prognostic and diagnostic biomarker.

MATERIAL AND METHODS

The present study employed a systematic review and meta-analysis approach, adhering to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) protocol (Supplementary material, *Table S1*) [17]. There was no patient or public involvement in this study. A full study protocol is available for this review and can be accessed on PROSPERO, an international register of systematic reviews (Record number: CRD42023468529). The data underlying this article will be shared upon reasonable request.

Data sources and searches

Two authors (MP and MT) independently conducted a comprehensive systematic review of the literature, encompassing all publications cited on the PubMed, Medline, Scopus, Embase, the Cochrane Central Register of Controlled Trials, and Clinicaltrial.gov databases, from its [What does "its" refer to??] inception to January 10, 2024. The search phrase employed for this purpose was as follows: "neutrophil-to-lymphocyte ratio" OR "neutrophil-to-lymphocyte ratio" OR "neutrophil/lymphocyte ratio" OR "neutrophil-lymphocyte ratio" OR "neutrophil-lymphocyte ratio" OR "Neutrophils to lymphocytes ratio" OR "Neutrophils-to-lymphocytes ratio" OR "neutrophils lymphocytes ratio" OR "neutrophils/lymphocytes ratio" OR "NLR" AND "acute coronary syndrome" OR "ACS" or "ST Segment Elevation Myocardial Infarction" OR "ST Elevated Myocardial Infarction" OR "ST-elevation MI" OR "STEMI" OR "non-ST elevation myocardial infraction" OR "NSTEMI" OR "myocardial Infarction" OR "unstable angina". Moreover, we searched the bibliographies of the target studies for additional references. If multiple publications from partially or completely overlapping cohorts were found, only the most recent publication with the larger sample size was included.

Inclusion and exclusion criteria

The inclusion criteria were randomized and non-randomized trials, as well as studies that reported NLR values in adult participants (aged ≥18 years) with different ACS forms. Reviews, meta-analyses, editorials, conference papers, case series with <10 participants, studies of pediatric populations, and non-English language studies were excluded.

Data extraction and quality assessment

Data was extracted by three independent reviewers (MP, MT, and LS) into a structured pro forma in an Excel sheet. Any discrepancies were resolved by consensus following a discussion with all the reviewers. Data on study characteristics (author, country, region, study design, sample sizes), patient demographics (baseline characteristics, major cardiovascular event [MACE] [Supplementary material, *Table S2*]), and NLR values were extracted. We extracted the mean and standard deviation or median and interquartile range for continuous variables and the number of patients belonging to each category for dichotomous variables.

Observational studies were appraised using the modified Newcastle-Ottawa Scale [18]. In each study, the domains that were assessed included the **representation of patients by the subjects [What do you mean??!**, selection of comparative groups, ascertainment of exposure and outcomes, and duration and comprehensiveness of follow-up, if applicable. The quality assessment of articles ranged from low (0–4), moderate (5–6), to high scores (7–9), representing three different levels of study quality.

Statistical analysis

The statistical analysis was performed in accordance with the recommendations of the Cochrane Collaboration and the standards for reporting the quality of meta-analyses [19]. Statistical analyses were performed using Review Manager software (version 5.4, Nordic Cochrane Centre, Cochrane Collaboration, Denmark) and Stata (version 14, StataCorp, College Station, TX, US). Outcomes were reported as the pooled odds ratio (OR), standard mean difference (SMD), and the corresponding 95% confidence intervals (95% CI). When the continuous outcome was reported as median, range, and interquartile range, we estimated means and standard deviations using the formula described by Hozo et al. [20]. Random-effects models were used for all analyses. Heterogeneity between studies was assessed quantitatively using the I2 statistic. I2 values of <50%, between 50% and 75%, and >75% were taken to represent low, moderate, and high degrees of heterogeneity, respectively. All tests were 2-sided and P-values <0.05 were considered statistically significant. We used Egger's test and funnel plots to check for potential bias and performed funnel plot tests for asymmetry to assess potential publication bias if there were more than ten trials in a single meta-analysis. Finally, in sensitivity analyses, leave-one-out analysis was performed.

RESULTS

Characteristics and quality assessments of included studies

The flow diagram of the study selection process is shown in Figure 1. In the primary search, a total of 1148 references were initially included. Of these, 443 articles were eliminated due to duplication, while additional 502 articles were omitted based on an assessment of their titles and abstracts. Following a comprehensive examination of 203 research studies, 113 were excluded due to their publication category (44 case reports/series, 18 abstracts, 17 letters/editorials, and 34 review articles). Finally, 90 articles were included in this meta-analysis [S1–S90].

Essential characteristics of the included studies are outlined in Supplementary material, *Table S3*. Overall, the 86 studies included in this meta-analysis provided a combined cohort of 45 990 patients. The sample size of studies varied from 59 to 6560 patients.

Of all analyzed studies, 90 were cohort studies, 34 were prospective studies, 42 were retrospective studies, and 14 were cross-sectional studies. The worldwide distribution of studies is presented in Figure 2. All studies had high quality based on Newcastle Ottawa Scale (Supplementary material, *Table S3*).

Meta-analysis

Pooled analysis of the NLR varied and was higher in ST-segment elevation myocardial infarction (STEMI) vs. non-ST elevation myocardial infarction (NSTEMI) patients; 4.94 ± 3.24 vs. 3.24 ± 2.74 (SMD = 0.61; 95% Cl, 0.39–0.83; P < 0.001; Figure 3). It also showed a difference between acute myocardial infarction (AMI) vs. unstable angina (UA) (4.47 ± 3.43 vs. 2.97 ± 1.58 ; SMD = 1.19; 95% Cl, 0.80-1.59; Figure 4), ACS vs. stable angina (SA) (5.45 ± 4.28 vs. 2.46 ± 2.15 ; SMD = 1.67; 95% Cl, 1.29-2.04; P < 0.001; Figure 5), and ACS vs. controls (SMD = 5.31 ± 4.01 vs. 2.46 ± 2.45 ; SMD = 0.93; 95% Cl, 0.70-1.16; P < 0.001; Figure 6).

The NLR also was associated with mortality in ACS, with survivors having lower results; 3.67 ± 2.72 vs. 5.56 ± 3.93 (SMD = -2.55; 95% Cl, -3.90 to -1.19; P < 0.001). Subanalysis showed that differences in the NLR were observed in STEMI survivors (4.28 ± 3.24 vs. 6.79 ± 3.98 ; SMD = -1.94; 95% Cl, -2.82 to -1.07; P < 0.001) but not observed in those with NSTEMI (SMD = -0.63; 95% Cl, -2.54 to 1.28; P = 0.52; Figure 7). No bias was found in the results of the studies in funnel plots of mortality risk.

Twenty-three studies also reported the relationship between NLR levels and MACE occurrence. Of ACS patients with MACE, the NLR was 6.29 \pm 4.89, compared to only 3.82 \pm 4.12 for those without MACE (SMD = 2.80; 95% Cl, 1.28 to 4.32; *P* <0.001). In the subgroup of patients with STEMI, the NLR was different between patients with and without MACE; 6.99 \pm 5.27 vs. 4.99 \pm 4.12, respectively (SMD = 1.85; 95% Cl, 0.90 to 2.80; *P* <0.001). In NSTEMI patients, the NLR ratio for those with and without MACE




Figure 1. Flow diagram of study selection




Figure 2. Worldwide distribution of studies included in the meta-analysis

Study or Subgroup			Total		STEMI	Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
Al-Sayed 2022		0.75	58	2.78		49	3.5%	0.76 [0.37, 1.16]	
Alain 2021		0.94	30	2.24		79	3.3%	2.19 [1.67, 2.70]	
Babes 2021		5.09	381	3.85		114	3.8%	0.31 [0.10, 0.52]	
Babes 2021 Bekler 2014	4.99		122	4.87		238	3.8%	0.06 [-0.16, 0.28]	
Damar 2022		5.26	75	5.56		63	3.6%	-0.04 [-0.38, 0.29]	
Erdoğan 2021		0.98	94	3.50	0.4	97	3.5%	2.65 [2.26, 3.04]	1
Ertürk 2017	6.13		104		2.36	101	3.3%		
	8.98			5.5 6.99				0.80 [0.52, 1.09]	
Guo 2018			396			261	3.9%	0.40 [0.24, 0.56]	T _
Karadeniz 2023		0.48	403	2.63		700	3.9%	1.19 [1.06, 1.32]	÷
Leylek 2020		2.89	49	3.05		51	3.5%	0.42 [0.02, 0.82]	
Li 2019		1.22	62	4.89		20	3.2%	-0.95 [-1.47, -0.42]	
Mansiroglu 2020		6.38	103	5.19	4.8	221	3.8%	0.51 [0.27, 0.75]	
Maréchal 2020	5	1.2	27	3.75		25	3.1%	1.22 [0.62, 1.82]	
Mayyas 2014	6.59		41	2.83		41	3.0%	3.01 [2.37, 3.65]	
Quisi 2021		2.53	218	2.79		200	3.8%	1.44 [1.23, 1.66]	-
Selanno 2022	17.76			10.75		93	3.8%	0.83 [0.56, 1.10]	
Setianingrum 2019	5.89	2.6	35	7.97		24	3.2%	-0.50 [-1.03, 0.03]	
Sheng 2021		2.24	24	3.58		25	3.2%	0.21 [-0.35, 0.77]	
Siddig 2020	3	0.9	70	6.8	5.9	15	3.1%	-1.47 [-2.07, -0.87]	
Sonmez 2015	5.1	5.6	45	5	5.2	65	3.6%	0.02 [-0.36, 0.40]	- <u>+</u> -
Sultana 2023	4.43	3.46	55	4.38	4.99	33	3.4%	0.01 [-0.42, 0.44]	_ _ _
Zazula 2007	6.9	5.7	45	4.8	3.7	65	3.5%	0.45 [0.07, 0.84]	
Zhan 2016	5.77	0.47	237	5.24	0.8	74	3.7%	0.93 [0.66, 1.21]	
Zhang 2019	4.35	0.89	59	2.92	0.38	100	3.5%	2.30 [1.89, 2.71]	
Zhang 2021	4.29	0.79	102	4.3	0.77	96	3.7%	-0.01 [-0.29, 0.27]	+
Zhang 2023	6.84	5.76	604	6.66	5.33	386	3.9%	0.03 [-0.10, 0.16]	+
Zuin 2017		1.95	2341	2.43	1.21	4219	4.0%	0.41 [0.36, 0.46]	· ·
Özbay 2020	5.64	4.22	225	5.3	3.5	141	3.8%	0.09 [-0.12, 0.30]	+
Total (95% CI)			6157			7596	100.0%	0.61 [0.39, 0.83]	•
Heterogeneity: Tau ² =	= 0.31: C	:hi² =	714.29	. df = 2	7 (P <	0.0000	()1); $I^2 = 9$	6%	-4 -2 0 2 4

Figure 3. Forest plot of the neutrophil-to-lymphocyte ratio in STEMI and NSTEMI patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line represents a 95% confidence interval. The diamonds represent pooled results

Abbreviations: CI, confidence interval; NSTEMI, non-ST-segment elevation myocardial infarction; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Al-Sayed 2022	3.06	0.72	107	0.93	0.08	23	5.2%	3.23 [2.63, 3.83]	
Bekler 2014	4.91	2.06	360	4.24	1.97	142	5.8%	0.33 [0.13, 0.52]	~
Ertürk 2017	4.74	3.78	205	2.61	1.59	114	5.8%	0.67 [0.43, 0.90]	-
Guo 2018	8.19	5.09	657	3.38	1.8	216	5.9%	1.07 [0.90, 1.23]	-
Li 2019	4.07	1.21	82	2.91	0.83	10	5.0%	0.98 [0.30, 1.65]	
Mansiroglu 2020	6.06	5.49	324	2.92	2.39	102	5.8%	0.64 [0.41, 0.86]	
Maréchal 2020	4.39	1.18	52	2.3	0.35	19	5.1%	2.01 [1.38, 2.63]	
Sheng 2021	3.79	2.05	49	2.68	1.68	156	5.7%	0.62 [0.30, 0.95]	
Siddig 2020	3.67	2.93	85	2.9	1.8	15	5.3%	0.27 [-0.28, 0.82]	
Sultana 2023	4.41	4.07	88	4	4.82	12	5.2%	0.10 [-0.51, 0.70]	- -
Tahto 2017	4.21	1.08	50	2.42	0.34	50	5.4%	2.22 [1.72, 2.72]	
Tenekecioglu 2015	3.95	1.91	101	3.25	1.32	83	5.7%	0.42 [0.12, 0.71]	
Zazula 2007	5.66	4.71	110	3.6	2.9	33	5.6%	0.47 [0.08, 0.86]	
Zhan 2016	5.64	0.61	311	2.97	0.43	65	5.5%	4.57 [4.15, 4.99]	
Zhang 2019	3.45	0.93	159	2.92	0.29	150	5.8%	0.76 [0.53, 0.99]	-
Zhang 2021	4.29	0.78	198	3.1	0.46	98	5.7%	1.72 [1.44, 2.00]	
Özbay 2020	5.6	3.6	148	2.6	1.3	399	5.8%	1.38 [1.17, 1.58]	-
Öztürk 2013	3.57	0.99	40	3.31	0.91	44	5.5%	0.27 [-0.16, 0.70]	
Total (95% CI)			3126			1731	100.0%	1.19 [0.80, 1.59]	•
Heterogeneity: Tau ²	= 0.68.0	[^] hi ² =	517 78	df =	17 (P 🛪	0 000	$(01) \cdot 1^2 = 9$		

Figure 4. Forest plot of the neutrophil-to-lymphocyte ratio in acute myocardial infarction (AMI) vs. unstable angina (UA) patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line represents a 95% confidence interval. The diamonds represent pooled results




Figure 5. Forest plot of the neutrophil-to-lymphocyte ratio in acute myocardial infarction (ACS) vs. stable angina (SA) patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line represents a 95% confidence interval. The diamonds represent pooled results

		ACS		Control			5	td. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bandara 2018	7	5.86	350	5.55	4.32	250	4.5%	0.27 [0.11, 0.44]	-
Canga 2018	2.39	0.91	52	1.63	0.22	30	4.3%	1.02 [0.54, 1.50]	
Cao 2023	5.85	0.97	284	1.98	0.23	91	4.3%	4.53 [4.13, 4.93]	-
Chawla 2019	7.3	5.8	84	2.1	0.7	32	4.3%	1.04 [0.61, 1.47]	-
Damar 2022	5.44	5.43	138	2.17	1.1	62	4.4%	0.71 [0.41, 1.02]	-
Del Turco 2022	5.3	4.3	361	2.6	3.4	806	4.5%	0.73 [0.60, 0.86]	•
Ertürk 2017	4	3.3	319	2.1	1.4	283	4.5%	0.73 [0.57, 0.90]	*
Gunes 2019	2.6	1.9	120	1.9	1.3	410	4.5%	0.48 [0.27, 0.69]	*
Haque 2022	3.88	2.24	138	1.63	0.33	134	4.5%	1.39 [1.13, 1.66]	
Li 2019	3.94	1.23	92	1.77	0.15	96	4.4%	2.49 [2.11, 2.88]	-
Nilsson 2014	2	0.25	20	1.53	0.18	37	4.0%	2.24 [1.55, 2.93]	
Rao 2019	8.67	2.06	48	2.09	0.45	48	3.9%	4.38 [3.63, 5.13]	
Setianingrum 2019	6.74	4.21	59	1.64	0.55	38	4.3%	1.53 [1.07, 1.99]	-
Shumilah 2021	6.5	3	100	1.9	0.9	100	4.4%	2.07 [1.72, 2.41]	
Sivri 2018	6.99	3.33	210	2.65	0.83	185	4.5%	1.74 [1.50, 1.97]	÷
Sonmez 2015	5.04	5.34	110	2.2	1	45	4.4%	0.62 [0.27, 0.98]	-
Topf 2022	4.02	0.88	63	2.14	0.26	68	4.2%	2.93 [2.43, 3.43]	-
Tsai 2017	3.6	3.7	131	2.2	1.2	114	4.5%	0.49 [0.24, 0.75]	-
Turkmen 2013	7.1	4.6	145	2.3	1.7	101	4.5%	1.29 [1.02, 1.57]	-
Yu 2016	4.93	3.15	349	2.14	1.97	251	4.5%	1.02 [0.85, 1.20]	*
Zazula 2007	5.18	4.44	143	3	1.6	38	4.4%	0.54 [0.18, 0.90]	-
Çaltekin 2020	5.61	0.75	86	2.09	0.2	82	3.9%	6.32 [5.57, 7.07]	
Öztürk 2013	3.43	0.95	84	2.61	0.64	40	4.4%	0.94 [0.55, 1.34]	-
Total (95% CI)			3486			3341	100.0%	1.67 [1.29, 2.04]	▲

Figure 6. Forest plot of the neutrophil-to-lymphocyte ratio in acute coronary syndrome (ACS) vs. control patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line represents a 95% confidence interval. The diamonds represent pooled results

		rvivor			surviv			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.5.1 ACS									
Babes 2021	3.52		849	6.45		87	11.1%	-0.67 [-0.89, -0.44]	*
Bajari 2017		3.39	353	7.92		47	11.1%	-1.12 [-1.44, -0.81]	*
Chen 2023			1418	8.71		132	11.1%	-7.54 [-7.86, -7.22]	*
Guo 2018	8.38			13.78		39	11.1%	-0.79 [-1.13, -0.45]	-
Kahraman 2022		0.62	475	5.25		50	11.1%	-2.06 [-2.38, -1.74]	-
Monteiro Junior 2018		0.49	411	9.39		55	11.0%	-6.33 [-6.83, -5.84]	-
Pieszko 2019			4287	3.88		766	11.2%	-3.31 [-3.41, -3.21]	
Sharma 2015	3.87		863	5.14		96	11.1%	-0.61 [-0.82, -0.40]	*
Yan 2020 Subtotal (95% CI)	3.83	2.86	370 9343	6.21	6.72		11.1% 100.0%	-0.55 [-0.74, -0.35] -2.55 [-3.90, -1.19]	★ [*]
Heterogeneity: $Tau^2 = \frac{1}{2}$	4.29: Ch	$i^2 = 2$	567.58	. df = 8	(P < 0	.00001	$ 1^2 = 100$	%	-
Test for overall effect:							,		
1.5.2 STEMI									
Akhter 2023	2.74	0.99	154	4.1	2.4	5	7.8%	-1.29 [-2.19, -0.39]	
Babes 2021	5.16	4.52	310	6.84	6.97	71	8.5%	-0.33 [-0.59, -0.07]	-
Ghaffari 2014	5.64	0.19	389	8.39	1.79	15	8.1%	-7.17 [-7.89, -6.46]	
Jadhav 2022	4.34	2.89	332	6.18	3.26	68	8.5%	-0.62 [-0.89, -0.36]	+
Lin 2021	7.07	5.24	157	10.44	4.85	24	8.4%	-0.65 [-1.08, -0.21]	-
Oh 2020	3.23	0.65	982	5.68	0.98	75	8.5%	-3.61 [-3.89, -3.33]	÷
Paul 2021	15.31	7.86	92	12.84	8.3	10	8.2%	0.31 [-0.34, 0.96]	
Sharma 2023	2.91	1.13	92	5.56	4.11	18	8.3%	-1.36 [-1.90, -0.82]	
Sigirci 2020	2.68	0.52	1086	4.18	0.75	102	8.5%	-2.76 [-2.99, -2.53]	÷
Siraj 2020	6.09	1.03	168	8.43	1.02	23	8.3%	-2.27 [-2.76, -1.77]	-
Tanriverdi 2017	5	4.3	338	8.9	6.1	30	8.4%	-0.87 [-1.25, -0.49]	-
Wang 2022 Subtotal (95% CI)	4.99	0.87	264 4364	7.93	1.38	132 573	8.5% 100.0%	-2.75 [-3.03, -2.47] -1.94 [-2.82, -1.07]	~
Heterogeneity: $Tau^2 =$	2.33: Ch	$i^2 = 7$	80.00.	df = 11	(P < 0	00001): $I^2 = 99\%$	6	-
Test for overall effect:	Z = 4.35	(P < 0	0.0001)				,		
1.5.3 NSTEMI									
Babes 2021	3.66	5.22	101	5.29	6.32	13	33.0%	-0.30 [-0.88, 0.28]	-
Guclu 2020	2.71	0.41	148	6	3.77	22	33.2%	-2.36 [-2.88, -1.85]	+
Karaoğlu 2021 Subtotal (95% CI)	4.44	4.2	60 309	2.6	1.57	199 234	33.8% 100.0%	0.75 [0.46, 1.05] - 0.63 [-2.54, 1.28]	-
Heterogeneity: $Tau^2 =$	2.79: Ch	$i^2 = 1$	06.37.	df = 2 (F	, < 0.0	0001):	$l^2 = 98\%$		-
Test for overall effect:				(
									-10 -5 0 5 10 Survivors Non-urvivors

Figure 7. Forest plot of the neutrophil-to-lymphocyte ratio in survivors vs. non-survivors in ACS, STEMI, and NSTEMI patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line represents a 95% confidence interval. The diamonds represent pooled results

Abbreviations: see Figure 3

L6.1 ACS Adam 2018 3.55 3.1 102 2.7 2.13 195 9.1% 0.34 0.10, 0.58] 3abes 2021 5.3 5.9 193 3.41 3.94 743 9.1% 0.43 10.27, 0.59] 3.427 5.82 5.427 5.827 5.827 1.827 5.85 5.267 5.257 5.267 5.26 5.267 5.27 5.27 5.28 5.287 5.280 1.280 1.280 5.280 1.280 5.280 1.280 1.280 5.280 1.280 1.280 5.280 1.280 1.280 5.280 1.280 1.280 1.280 1.280 1.280 1.280 1.280 1.280 1.280 1.280 5.182 5.		Com	olicatio	ons	No Cor	nplicati	ions	9	Std. Mean Difference	Std. Mean Difference	
Adam 2018 3.55 3.1 102 2.7 2.13 195 9.1% 0.34 [0.10, 0.58] Sabes 2021 5.3 5.9 193 3.41 3.94 743 9.1% 0.43 [0.27, 0.59] Siccirè 2023 6.63 1.32 71 3.6 0.63 398 9.1% 3.91 3.55, 4.27] Then 2020 8.11 1.92 20 6.39 2.69 87 9.1% 0.67 [0.17, 1.16] Su 2021 4.19 0.79 98 2.15 0.25 952 9.1% 5.02 [4.67, 5.37] Huang 2009 1.244 6.82 167 1.434 8.31 456 9.1% -0.24 [-0.42, -0.07] mmanuel 2021 4.82 7.39 31 4.35 3.23 28 9.0% 0.08 [-0.43, 0.59] Caradeniz 2023 6.53 0.82 195 2.35 0.27 908 9.1% 9.89 [9.44, 10.3] J 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] J 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 5.14 [2.42, 3.36] Subtotal (95% CI) 109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Chi ² = 3157.85, df = 10 (P < 0.00001); l ² = 100% Fest for overall effect: Z = 3.62 (P = 0.0003) L6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.13% 1.39 [0.95, 1.82] adhav 2022 5.2 3.01 181 4.15 2.36 219 11.3% 0.35 [0.15, 0.55] Caradeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.3], 10.80] Consibi 2017 10.8 7 68 6.6 4.6 263 11.33% 0.81 [0.54, 1.08] Drole 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Charage 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2.216 110.00% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Fest for overall effect: Z = 3.80 (P = 0.0001) L6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Subtotal (95% CI) 647 2.21 12.25 0.00.09 2.18 (0.55, 1.32] Subtotal (95% CI) 647 2.22 1.256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 2.30; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Fest for overall effect: Z = 3.80 (P = 0.100) Heterogeneity: Tau ² = 2.151; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Fest for overall effect: Z = 1.64 (P = 0.10) Heterogeneity: Tau ² = 2.13; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Fest for	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Babes 2021 5.3 5.9 193 3.41 3.94 743 9.1% 0.43 $[0.27, 0.59]$ Babes 2021 6.3 1.32 71 3.6 0.63 398 9.1% 3.91 [3.55, 4.27] Chen 2020 8.11 1.92 20 6.39 2.69 87 9.1% 0.67 $[0.17, 1.16]$ Gu 2021 4.19 0.79 98 2.15 0.29 552 9.1% 5.02 [4.67, 5.37] Huang 2009 12.41 6.82 167 14.34 8.31 456 9.1% $-0.24 [-0.42, -0.07]$ Immanuel 2021 4.62 7.39 31 4.35 3.22 8 9.0% 0.08 $[-0.43, 0.59]$ Karadeniz 2023 6.43 0.82 195 2.35 0.27 908 9.1% 9.89 [9.44, 10.33] Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 5.13 [4.74, 5.53] Li 2022 5.24 0.81 81 2.96 0.039 421 9.1% 5.13 [4.74, 5.53] Li 2022 5.24 0.81 81 2.96 0.039 421 9.1% 5.13 [4.74, 5.53] Li 2022 5.29 0.29 107 2.27 0.2 1594 9.1% 5.13 [4.74, 5.53] Li 2022 7.29 0.29 107 2.27 0.2 1594 9.1% 5.13 [4.74, 5.53] Li 2022 7.2 0.2 1109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Ch ² = 3157.85, df = 10 (P < 0.00001); l ² = 100% Test for overall effect: Z = 3.62 (P = 0.0003) L6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.06, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.06% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.06% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.66% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.66% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [0.48, 10.54] Karadeniz 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Pehphani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.50 [0.26, 0.74] Karadeniz 2024 4.23 0.3 88 [19 2.2	1.6.1 ACS										
Bic(ric 2023 6.63 1.32 71 3.6 0.63 398 9.1% 3.91 [3.5, 4.27] Chen 2020 8.11 1.92 20 6.39 2.69 87 9.1% 0.67 [0.17, 1.16] Gu 2021 4.19 0.79 98 2.15 0.29 552 9.1% 5.02 [4.67, 5.37] Hoang Ngo 2023 4.73 0.78 44 3.19 0.54 98 9.1% 2.46 [2.00, 2.91] Immanuel 2021 4.82 7.39 31 4.35 3.23 28 9.0% 0.08 [-0.43, 0.59] Karadeniz 2023 6.53 0.82 195 2.35 0.27 908 9.1% 9.89 [9.44, 10.33] Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 9.14 [2.2, 3.66] Subtotal (95% CI) 1109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau" = 6.55; Chi ² = 3157.85, df = 10 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) L6.2 STEMI Ahmed 202 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 2219 11.3% 0.32 [0.17, 0.85] Her 2017 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.05 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 2.49% 10.05 [0.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.08 [-0.33, 0.50] Heterogeneity: Tau" = 2.208; Chi ² = 696.28, df = 8 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) L6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 647 22 2.125 10.00% 2.88 [-0.56, 6.33] Heterogeneity: Tau" = 12.31; Chi ² = 1002.36, df = 3 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 1.64 (P	Adam 2018	3.55	3.1	102	2.7	2.13	195	9.1%	0.34 [0.10, 0.58]	-	
Chen 2020 8.11 1.92 20 6.39 2.69 87 9.1% 0.67 [0.17, 1.16] Gu 2021 4.19 0.79 98 2.15 0.29 552 9.1% 5.02 [4.67, 5.37] Huang 2003 12.41 6.82 167 14.34 8.31 456 9.1% -0.24 [-0.42, -0.7] Immanuel 2021 4.82 7.39 31 4.35 3.23 28 9.0% 0.08 [-0.43, 0.59] Karadeniz 2023 6.53 0.82 195 2.35 0.27 908 9.1% 9.89 [9.44, 10.33] Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 9.89 [9.44, 10.33] Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 3.14 [2.92, 3.36] Subtoal (95% CI) 109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Ch ² = 3157.85, df = 10 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) L6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hatropo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Het 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Hadhav 2022 5.2 3.01 181 4.15 2.96 219 1.13% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 1.080] Konsihi 2017 10.8 7 68 6.6 4.6 263 11.33 (0.081 [0.54, 1.08] Oncel 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.17, 0.86] Subtoal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) L6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 2.49% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 2.50% 0.94 [0.55, 1.32] Subtoal (95% CI) 226 2.25 581 2.49% 10.000 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 2.50% 0.94 [0.55, 1.32] Subtoal (95% CI) 262 1.256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 1.23; Chi ² = 1002.36, df = 3 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 1.64 ($P = 0.10$)	Babes 2021	5.3	5.9	193	3.41	3.94	743	9.1%	0.43 [0.27, 0.59]	•	
Gu 2021 419 0.79 98 2.15 0.29 552 9.1% 5.02 [4.67, 5.37] Hoang Ngo 2023 4.73 0.78 44 3.19 0.54 98 9.1% 2.46 [2.00, 2.91] Huang 2009 12.41 6.82 167 14.34 8.31 456 9.1% -0.24 [-0.42, -0.07] Immanuel 2021 4.82 7.39 31 4.35 3.23 28 9.0% 0.08 [-0.43, 0.59] Karadeniz 2023 6.53 0.82 195 2.35 0.27 908 9.1% 9.89 [9.44, 10.33] Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] Li 2020 2.9.2 0.29 107 2.27 0.2 1594 9.1% 3.14 [2.92, 3.36] Subtotal (95% CI) 109 5480 100.0% 2.26 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Ch ² = 3157.85, df = 10 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) L62 STEM Anreadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 21 1.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.85 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.56] Subtotal (95% CI) 647 2.216 10.00% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) L6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.55 [0.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 642 32 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 2.23 2.25 581 2.49% 10.005 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 2.23 2.25 581 2.49% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 2.23 2.25 581 2.49% 10.00% Test for overall effect: Z = 1.64 ($P = 0.10$)	Biccirè 2023	6.63	1.32	71	3.6	0.63	398	9.1%	3.91 [3.55, 4.27]		
Hoang Ngo 2023 4.73 0.78 44 3.19 0.54 98 9.1% 2.46 [2.00, 2.91] Huang 2009 12.41 6.82 167 14.34 8.31 456 9.1% -0.24 [-0.42, -0.07] Immanuel 2021 4.82 7.39 31 4.33 3.23 28 9.0% 0.08 [-0.43, 0.59] Karadeniz 2023 6.53 0.82 195 2.35 0.27 908 9.1% 9.89 [9.44, 10.33] Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 3.14 [2.92, 3.36] Subtotal (95% CI) 109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Ch ² = 3157.85, df = 10 (P < 0.00001); l ² = 100% Test for overall effect: Z = 3.62 (P = 0.0003) L6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.3], 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.35 [0.15, 0.55] Subtotal (95% CI) 647 6.31 1.307 1.77 90 10.6% 2.95 [2.0, 3.70] Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.05 [0.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 2.13; Ch ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 3.60 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Ch ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Chen 2020	8.11	1.92	20	6.39	2.69	87	9.1%	0.67 [0.17, 1.16]		
Huang 2009 12.41 6.82 167 14.34 8.31 456 9.1% -0.24 [-0.42, -0.07] Immanuel 2021 4.82 7.39 31 4.35 3.23 28 9.0% 0.08 [-0.43, 0.59] Karadeniz 2023 6.53 0.82 195 2.35 0.27 908 9.1% 9.89 [9.44, 10.33] Li 2020 2.92 0.29 107 2.27 0.2 1594 9.1% 5.13 [4.74, 5.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 3.14 [2.92, 3.36] Subtotal (95% CI) 109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Ch ² = 3157.85, df = 10 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) L6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.06, 0.53] Heterogeneity: Tau ² = 2.3 6.05 7 6 2.6 0.3 327 10.6% 1.06 [9.31, 10.80] Konishi 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) L6.3 NSTEMI Babes 2021 6.43 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.15, 0.58[Subtotal (95% CI) 262 1255 12.49 212 11.2% 0.51 [0.15, 0.58[Subtotal (95% CI) 262 1255 12.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.98 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 9.223 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 df = 8 ($P < 0.00001$); l ² = 90% Test for overall effect: Z = 3.80 ($P = 0.0001$) L6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1255 100.00% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 1.64 ($P = 0.10$)	Gu 2021	4.19	0.79	98	2.15	0.29	552	9.1%	5.02 [4.67, 5.37]		
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Hoang Ngo 2023	4.73		44	3.19		98	9.1%	2.46 [2.00, 2.91]	· · ·	
Karadeniz 2023 6.53 0.82 195 2.35 0.27 908 9.1% 9.89 [9.4,4,10.33] Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.4, 10.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 3.14 [2.92, 3.6] Subtotal (95% CI) 1109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Ch ² = 3157.85, df = 10 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) 1.6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Koradeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Cheel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 22161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Ch ² = 6.02, 8. df = 8 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.68 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 2.662 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Ch ² = 1002.36, df = 3 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 1.64 ($P = 0.10$)	Huang 2009	12.41	6.82	167	14.34	8.31	456	9.1%	-0.24 [-0.42, -0.07]		
Li 2020 5.44 0.81 81 2.96 0.39 421 9.1% 5.13 [4.74, 5.53] Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 3.14 [2.92, 3.36] Subtotal (95% CI) 1109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Chi ² = 3157.85, df = 10 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) 1.6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) 1.63 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.98 [-0.53, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.98 [-0.55, 6.33] Heterogeneity: Tau ² = 1.2.31; Chi ² = 1002.36, df = 3 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 1.64 ($P = 0.10$)	Immanuel 2021	4.82	7.39	31	4.35	3.23	28	9.0%	0.08 [-0.43, 0.59]	I +	
Li 2022 2.92 0.29 107 2.27 0.2 1594 9.1% 3.14 [2.92, 3.36] Subtotal (95% CI) 109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Ch ² = 3157.85, df = 10 ($P < 0.00001$); I ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) 1.6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadha 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 ($P < 0.00001$); I ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Debqhani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.68 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 1.2.31; Chi ² = 1002.36, df = 3 ($P < 0.00001$); I ² = 100% Test for overall effect: Z = 1.64 ($P = 0.10$)	Karadeniz 2023	6.53	0.82	195	2.35	0.27	908	9.1%	9.89 [9.44, 10.33]	-	-
Subtotal (95% CI) 1109 5480 100.0% 2.80 [1.28, 4.32] Heterogeneity: Tau ² = 6.55; Chi ² = 3157.85, df = 10 ($P < 0.00001$); i ² = 100% Test for overall effect: Z = 3.62 ($P = 0.0003$) 1.6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Hetero17 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 3.80 ($P = 0.0001$) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 12.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 1.2.31; Chi ² = 1002.36, df = 3 ($P < 0.00001$); l ² = 100% Test for overall effect: Z = 1.64 ($P = 0.10$)	Li 2020	5.44	0.81	81	2.96	0.39	421	9.1%	5.13 [4.74, 5.53]		
Heterogeneity: Tau ² = 6.55; Chi ² = 3157.85, df = 10 (P < 0.00001); I ² = 100% Test for overall effect: Z = 3.62 (P = 0.0003) 1.6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [0.33, 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); I ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 1.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)		2.92	0.29		2.27	0.2					
Test for overall effect: $Z = 3.62$ (P = 0.0003) 1.6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Moncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.050 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.22 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)										\bullet	
1.6.2 STEMI Ahmed 2020 7.8 7.4 79 6.1 5.5 528 11.3% 0.29 [0.06, 0.53] Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [-0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 1.2.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)						0 (P < 0	.00001); $I^2 = 100$	0%		
Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.68 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Test for overall effec	zt: Z = 3.6	52 (P =	0.0003	3)						
Babes 2021 6.47 6.31 120 5.01 4.36 261 11.3% 0.29 [0.07, 0.51] Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	1.6.2 STEMI										
Hartopo 2015 7.9 4.8 49 5.7 4.1 116 11.2% 0.51 [0.17, 0.85] Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Ahmed 2020	7.8	7.4	79	6.1	5.5	528	11.3%	0.29 [0.06, 0.53]	-	
Her 2017 8.46 6.09 27 3.56 2.81 145 11.1% 1.39 [0.95, 1.82] Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% 0.35 [0.15, 0.55] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 2.95 [2.20, 3.70] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Babes 2021	6.47	6.31	120	5.01	4.36	261	11.3%	0.29 [0.07, 0.51]	-	
Jadhav 2022 5.2 3.01 181 4.15 2.96 219 11.3% $0.35[0.15, 0.55]$ Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 [9.31, 10.80] Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% Cl) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.63 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Hartopo 2015	7.9	4.8	49	5.7	4.1	116	11.2%	0.51 [0.17, 0.85]	-	
Karadeniz 2023 6.53 0.65 76 2.6 0.3 327 10.6% 10.06 9.31 10.80 Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 $[0.54, 1.08]$ Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 $[2.20, 3.70]$ Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 $[0.15, 0.86]$ Subtotal (95% CI) 647 2161 100.0% 1.85 $[0.90, 2.80]$ Heterogeneity: Tau ² = 2.08 ; Chi ² = 696.28, df = 8 (P < 0.00001); $l2 = 99\%$ 1.85 $[0.90, 2.80]$ Ibighani 2014 2.3 0.3 811 5.45 84 25.0% 0.81 $[0.26, 0.74]$ Karadeniz 2023 6.53 0.88 119 2.23 0.25 5812 4.9% 10.05 9.48 10.61] 9.36 Wang 2020 4.23 2.36 32 2.79 1.34 182 <td>Her 2017</td> <td>8.46</td> <td>6.09</td> <td>27</td> <td>3.56</td> <td>2.81</td> <td>145</td> <td>11.1%</td> <td>1.39 [0.95, 1.82]</td> <td></td> <td></td>	Her 2017	8.46	6.09	27	3.56	2.81	145	11.1%	1.39 [0.95, 1.82]		
Konishi 2017 10.8 7 68 6.6 4.6 263 11.3% 0.81 [0.54, 1.08] Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Jadhav 2022	5.2	3.01	181	4.15	2.96	219	11.3%	0.35 [0.15, 0.55]	-	
Oncel 2015 8.18 1.16 11 3.07 1.77 90 10.6% 2.95 [2.20, 3.70] Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtoal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtoal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Karadeniz 2023	6.53	0.65	76	2.6	0.3	327	10.6%	10.06 [9.31, 10.80]	-	
Zhang 2015 7.04 2.09 36 6.23 1.49 212 11.2% 0.51 [0.15, 0.86] Subtotal (95% CI) 647 2161 100.0% 1.85 [0.90, 2.80] Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); l ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Konishi 2017	10.8	7	68	6.6	4.6	263	11.3%	0.81 [0.54, 1.08]		
Subtotal (95% Cl) 647 2161 100.0% 1.85 $[0.90, 2.80]$ Heterogeneity: Tau ² = 2.08; Chi ² = 696.28, df = 8 (P < 0.00001); I ² = 99% Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Oncel 2015	8.18	1.16	11	3.07	1.77	90	10.6%	2.95 [2.20, 3.70]	· · · · · · · · · · · · · · · · · · ·	
Heterogeneity: $Tau^2 = 2.08$; $Chi^2 = 696.28$, $df = 8$ (P < 0.00001); $l^2 = 99\%$ Test for overall effect: Z = 3.80 (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Zhang 2015	7.04	2.09	36	6.23	1.49	212	11.2%			
Test for overall effect: $Z = 3.80$ (P = 0.0001) 1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)									1.85 [0.90, 2.80]	◆	
1.6.3 NSTEMI Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); l ² = 100% Test for overall effect: $Z = 1.64$ (P = 0.10)	Heterogeneity: Tau ²	= 2.08; 0	$Chi^2 = 6$	696.28,	df = 8 (P < 0.0	0001); I	$^{2} = 99\%$			
Babes 2021 4.26 5.03 30 3.81 5.45 84 25.0% 0.08 [-0.33, 0.50] Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	Test for overall effec	zt: Z = 3.8	80 (P =	0.0001	L)						
Dehghani 2014 2.3 0.3 81 2.15 0.3 409 25.1% 0.50 [0.26, 0.74] Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10)	1.6.3 NSTEMI										
Karadeniz 2023 6.53 0.88 119 2.23 0.25 581 24.9% 10.05 [9.48, 10.61] Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% 0.94 [0.55, 1.32] Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10) -10 -5 0 5 10	Babes 2021	4.26	5.03	30	3.81	5.45	84	25.0%	0.08 [-0.33, 0.50]	I +	
Wang 2020 4.23 2.36 32 2.79 1.34 182 25.0% $0.94 [0.55, 1.32]$ Subtotal (95% CI) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10) -10 -5 0 5 10	Dehghani 2014	2.3	0.3	81	2.15	0.3	409	25.1%	0.50 [0.26, 0.74]	•	
Subtotal (95% Cl) 262 1256 100.0% 2.88 [-0.56, 6.33] Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10) -10 -5 0 5 10	Karadeniz 2023	6.53	0.88	119	2.23	0.25	581	24.9%	10.05 [9.48, 10.61]	-	-
Heterogeneity: Tau ² = 12.31; Chi ² = 1002.36, df = 3 (P < 0.00001); I ² = 100% Test for overall effect: Z = 1.64 (P = 0.10) -10 -5 0 5 10		4.23	2.36		2.79	1.34					
Test for overall effect: $Z = 1.64$ (P = 0.10) -10 -5 0 5 10	Subtotal (95% CI)			262			1256	100.0%	2.88 [-0.56, 6.33]		
					36, df =	3 (P < 0	.00001); $I^2 = 100$	0%		
	Test for overall effec	t: $Z = 1.6$	64 (P =	0.10)							
										- <u>+</u>	+
Complications Non-complications											10
										complications Non-complications	

Figure 8. Forest plot of the neutrophil-to-lymphocyte ratio for major cardiovascular events (MACE) and non-MACE in ACS, STEMI, and NSTEMI patients. The center of each square represents the standardized mean differences for individual trials, and the corresponding horizontal line represents a 95% confidence interval. The diamonds represent pooled results

Abbreviations: see Figure 3

was 4.86 ± 2.69 vs. 2.39 ± 1.59 , respectively (SMD = 2.88; 95% CI, 2.88; 95% CI, -0.56 to 6.33; *P* = 0.10; Figure 8). No bias was found in the results of the studies on funnel plots of MACE risk.

DISCUSSION

Our meta-analysis showed that the NLR was higher in AMI vs. UA, ACS vs. SA, ACS vs. controls, and ACS survivors vs. ACS deceased. The NLR was also higher for patients suffering a MACE compared to those without a MACE-based endpoint. Considering the above results as well as the wide availability and cost-effectiveness of the NLR index, our meta-analysis has suggested the potential good predictive and diagnostic properties of the NLR in ACS patients. Furthermore, our meta-analysis showed that the NLR may be a good predictor of MACE risk, at least in STEMI patients. The latter may be particularly useful in routine clinical settings.

Other meta-analyses conducted to date have provided results similar to our findings. In a 2018 meta-analysis that included 14 studies and 10 245 post-STEMI patients after percutaneous coronary intervention, the authors found NLR differences in numerous parameters (mortality, MACE, stent thrombosis, long-term mortality, etc.). Furthermore, compared to other meta-analyses, as well as ours, the population included in the just-mentioned analysis was more homogeneous [21]. Moreover, in a meta-analysis by Dong et al, the authors reported that an increased NLR before ACS treatment was associated with poor long-term prognosis and higher in-hospital mortality compared to patients with lower NLR values. Importantly, their work proposed an NLR cut-off of 5.0 as a risk estimation after ACS [22]. Taking into account the results of our meta-analysis and the previously presented meta-analyses [23], a 5.0 risk stratification cut-off point seems reasonable.

Other meta-analyses have indirectly suggested NLR value in predicting cardiovascular risk, thus supporting its use in cardiovascular medicine. For example, the NLR may predict cardiovascular or all-cause mortality in patients with chronic kidney disease as shown by a 2021 meta-analysis in which a higher NLR rate was associated with increased risk of cardiovascular mortality (HR 1.45; 95% Cl, 1.18–1.79; P < 0.001) [24]. The same conclusion was reported in another meta-analysis [25]. The NLR may also be a useful biomarker in differentiating patients requiring in-depth diagnostics for coronary artery abnormalities and in patients with Kawasaki disease [26]. In the context

of acute pulmonary embolism, the NLR turned out to be a good predictor of short-term (in-hospital and 30-day) mortality and long-term mortality [27]. Additionally, when assessing the predictive properties of the NLR, it should be taken into account that recognized cardiovascular risk factors are also associated with an increased NLR value. Thus, poor glycemic control, as indicated by elevated HbA1c, leads to increased NLR values [28]. A similarly an elevated NLR is observed in patients with hypertension [29].

Compared to other biomarkers of the systematic inflammatory response, the NLR is easier to obtain; a basic blood count is sufficient [30, 31]. Moreover, compared to other leukocyte subtypes, it is a more stable biomarker [32]. Thus, the NLR is an effective and cost-effective alternative to other biomarkers. As with most biomarkers, studies are needed to demonstrate the true prognostic value of the cut-off.

Considering the above, the predictive properties of the NLR in the context of MACE risk seem to be the most clinically useful. Identifying patients at the highest risk of developing MACE within a predictable and well-defined time frame remains a significant clinical challenge. Identification of patients at risk of MACE may lead to more optimized care for this group of patients. However, our meta-analysis showed some limitations in this context, primarily the lack of statistical significance for patients with NSTEMI (NLR for those with and without MACE was 4.86 ± 2.69 vs. 2.39 ± 1.59, respectively; SMD = 2.88; 95% Cl, 2.88; 95% Cl, -0.56 to 6.33; P = 0.10). Therefore, the clinical usefulness of the NLR would be limited to STEMI patients, for whom statistical significance was obtained. This difference seems justified on the basis of basic science. Since in the course of STEMI, myocardial damage and microvascular obstruction are usually more prominent compared to NSTEMI, activation of the immune system is more expected, leading to an increased NLR value [33, 34]. Further research, in particular, to confirm the usefulness of the predictive properties of the NLR in the context of MACE, is needed. Research should also define the time interval in which NLR-based prediction is most accurate as well as indicate for which outcomes (defined variously in studies as components of the composite MACE endpoint) the predictive properties of the NLR may be most useful.

Limitations of the study

Some limitations of the current meta-analysis should be highlighted. As the summation of the totality of the data was derived from retrospective analyses, prospective validation would still be of value to determine the impact of interventions applied to patients identified by the NLR as high-risk. Finally, although others have evaluated a broader spectrum of cardiovascular diseases, our analysis was limited to only adult patients with acute coronary syndromes; therefore, our conclusions must be restricted to this cohort. Ultimately, despite these limitations, the large sample size analyzed in this study suggests that the NLR is an excellent predictor of outcomes in selected patients with specific cardiovascular pathology.

CONCLUSIONS

Overall, we evaluated 86 studies, involving 44 486 patients and concluded that NLR is an effective tool for differentiating between different types of ACS. A high NLR is associated with ACS and increased MACE at 30 days. The NLR also appears to be a good predictor of MACE risk, at least in STEMI patients. Further research should aim to confirm in which patient population the NLR has the best predictive properties, what time frame is acceptable, and for which MACE the NLR shows predictive properties.

Supplementary material

Supplementary material is available at https://journals. viamedica.pl/polish_heart_journal.

Article information

Conflict of interest: None declared.

Funding: None.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at polishheartjournal@ptkardio.pl

REFERENCES

- Gozukucuk R, Kılıc HH, Uyanik BS, et al. The İmportance of hematological parameters in the prognosis of patients with severe COVID-19, A single-center retrospective study. Niger J Clin Pract. 2023; 26(9): 1297–1302, doi: 10.4103/njcp.njcp_22_23, indexed in Pubmed: 37794542.
- Mahajan M, Prasad MK, Ashok C, et al. The Correlation of the Neutrophil-to-Lymphocyte Ratio With Microvascular Complications in Patients With Diabetes Mellitus. Cureus. 2023; 15(9): e44601, doi: 10.7759/cureus.44601, indexed in Pubmed: 37799262.
- Kaźmierska J, Bajon T, Winiecki T, et al. Significance of neutrophil to lymphocyte ratio as a predictor of outcome in head and neck cancer treated with definitive chemoradiation. Rep Pract Oncol Radiother. 2023; 28(3): 389–398, doi: 10.5603/RPOR.a2023.0042, indexed in Pubmed: 37795402.
- He YM, Liu X, Zhong SY, et al. Neutrophil-to-lymphocyte ratio in relation to trauma severity as prognosis factors in patients with multiple injuries complicated by multiple organ dysfunction syndrome: A retrospective analysis. Immun Inflamm Dis. 2023; 11(9): e1031, doi: 10.1002/iid3.1031, indexed in Pubmed: 37773708.
- Kusama H, Kittaka N, Soma Ai, et al. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer. Breast Cancer. 2023; 30(6): 1085–1093, doi: 10.1007/s12282-023-01504-y, indexed in Pubmed: 37782377.
- Ha ET, Yee A, Peterson SJ, et al. Neutrophil-to-lymphocyte ratio and prognosis in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Cardiovasc Revasc Med. 2023 [Epub ahead of print], doi: 10.1016/j.carrev.2023.09.003, indexed in Pubmed: 37714727.
- Khan UH, Pala MR, Hafeez I, et al. Prognostic value of hematological parameters in older adult patients with acute coronary syndrome undergoing coronary intervention: a single centre prospective study. J Geriatr Cardiol. 2023; 20(8): 596–601, doi: 10.26599/1671-5411.2023.08.008, indexed in Pubmed: 37675260.
- Wu CC, Wu CH, Lee CH, et al. Association between neutrophil percentage-to-albumin ratio (NPAR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and long-term mortality in community-dwelling adults with heart failure: evidence from US NHANES

2005-2016. BMC Cardiovasc Disord. 2023; 23(1): 312, doi: 10.1186/s12872-023-03316-6, indexed in Pubmed: 37344786.

- Szarpak L, Lapinski M, Gasecka A, et al. Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients. J Cardiovasc Dev Dis. 2021; 9(1), doi: 10.3390/jcdd9010006, indexed in Pubmed: 35050216.
- Gąsecka A, Rogula S, Szarpak Ł, et al. LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis. Life (Basel). 2021; 11(1), doi: 10.3390/life11010039, indexed in Pubmed: 33440673.
- 11. García-Escobar A, Vera-Vera S, Tébar-Márquez D, et al. Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: New insights for a potential predictor of anti-cytokine therapy responsiveness. Microvasc Res. 2023; 150: 104598, doi: 10.1016/j.mvr.2023.104598, indexed in Pubmed: 37633337.
- Hanna A, Frangogiannis NG. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Cardiovasc Drugs Ther. 2020; 34(6): 849–863, doi: 10.1007/s10557-020-07071-0, indexed in Pubmed: 32902739.
- Sanders-van Wijk S, van Empel V, Davarzani N, et al. TIME-CHF investigators. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015; 17(10): 1006–1014, doi: 10.1002/ejhf.414, indexed in Pubmed: 26472682.
- Maierean S, Webb R, Banach M, et al. The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events. Eur Heart J Open. 2022; 2(4): oeac039, doi: 10.1093/ehjopen/oeac039, indexed in Pubmed: 35919577.
- Seegobin K, Alhaj Moustafa M, Majeed U, et al. Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. J Blood Med. 2021; 12: 1037–1043, doi: 10.2147/JBM.S340361, indexed in Pubmed: 34916863.
- Chaffey L, Roberti A, Greaves DR. Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities. Front Pharmacol. 2022; 13: 1046406, doi: 10.3389/fphar.2022.1046406, indexed in Pubmed: 36339576.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71, doi: 10.1136/bmj.n71.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9): 603–605, doi: 10.1007/s10654-010-9491-z, indexed in Pubmed: 20652370.
- Higgins JPT, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928, doi: 10.1136/bmj.d5928, indexed in Pubmed: 22008217.
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5: 13, doi: 10.1186/1471-2288-5-13, indexed in Pubmed: 15840177.
- Zhang S, Diao J, Qi C, et al. Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis. BMC Cardiovasc Disord. 2018; 18(1): 75, doi: 10.1186/s12872-018-0812-6, indexed in Pubmed: 29716535.

- Dong CH, Wang ZM, Chen SY. Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary syndrome: A systematic review and meta-analysis. Clin Biochem. 2018; 52: 131–136, doi: 10.1016/j.clinbiochem.2017.11.008, indexed in Pubmed: 29132766.
- Wang X, Zhang G, Jiang X, et al. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. Atherosclerosis. 2014; 234(1): 206–213, doi: 10.1016/j.atherosclerosis.2014.03.003, indexed in Pubmed: 24681815.
- Ao G, Wang Y, Qi X, et al. Association of neutrophil-to-lymphocyte ratio and risk of cardiovascular or all-cause mortality in chronic kidney disease: a meta-analysis. Clin Exp Nephrol. 2021; 25(2): 157–165, doi: 10.1007/s10157-020-01975-9, indexed in Pubmed: 33025234.
- Zhao WM, Tao SM, Liu GL. Neutrophil-to-lymphocyte ratio in relation to the risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2020; 42(1): 1059–1066, doi: 10.1080/0886022X.2020.1832521, indexed in Pubmed: 33081569.
- Sarejloo S, Shahri MM, Azami P, et al. Neutrophil to Lymphocyte Ratio as a Biomarker for Predicting the Coronary Artery Abnormality in Kawasaki Disease: A Meta-Analysis. Dis Markers. 2022; 2022: 6421543, doi: 10.1155/2022/6421543, indexed in Pubmed: 36267460.
- Wang Q, Ma J, Jiang Z, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. Int Angiol. 2018; 37(1): 4–11, doi: 10.23736/S0392-9590.17.03848-2, indexed in Pubmed: 28541022.
- Adane T, Melku M, Worku YB, et al. The Association between Neutrophil-to-Lymphocyte Ratio and Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Diabetes Res. 2023; 2023: 3117396, doi: 10.1155/2023/3117396, indexed in Pubmed: 37305430.
- Sarejloo S, Dehesh M, Fathi M, et al. Meta-analysis of differences in neutrophil to lymphocyte ratio between hypertensive and non-hypertensive individuals. BMC Cardiovasc Disord. 2023; 23(1): 283, doi: 10.1186/s12872-023-03304-w, indexed in Pubmed: 37270484.
- Pruc M, Jannasz I, Swieczkowski D, et al. Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis. Cardiol J. 2023 [Epub ahead of print], doi: 10.5603/cj.96228, indexed in Pubmed: 37772350.
- Çaltekin İ, Demirtaş E. Is platelet to monocyte ratio a useful inflammatory determinant of ST-elevation myocardial infarction? Disaster and Emergency Medicine Journal. 2020, doi: 10.5603/demj.a2020.0045.
- Ji Z, Liu G, Guo J, et al. The Neutrophil-to-Lymphocyte Ratio Is an Important Indicator Predicting In-Hospital Death in AMI Patients. Front Cardiovasc Med. 2021; 8: 706852, doi: 10.3389/fcvm.2021.706852, indexed in Pubmed: 34616780.
- Guerra E, Hadamitzky M, Ndrepepa G, et al. Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. Int J Cardiovasc Imaging. 2014; 30(6): 1087–1095, doi: 10.1007/s10554-014-0430-z, indexed in Pubmed: 24781031.
- Plein S, Younger JF, Sparrow P, et al. Cardiovascular magnetic resonance of scar and ischemia burden early after acute ST elevation and non-ST elevation myocardial infarction. J Cardiovasc Magn Reson. 2008; 10(1):47, doi: 10.1186/1532-429X-10-47, indexed in Pubmed: 18950527.